Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 4/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | PGK1 | P00558 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182533 | 0.89 | PIK3CD (0.71) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL5569427 | 0.86 | KIT (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGKCNH2 | |
| SCHEMBL5568255 | 0.81 | KIT (0.64) | KITEGFRERBB2KDRRAF1 | |
| SCHEMBL6181412 | 0.79 | EGFR (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGKIT | |
| SCHEMBL4782102 | 0.79 | WHR1 (0.61) | KITEGFRKDR | |
| SCHEMBL2126095 | 0.78 | EGFR (0.61) | KITEGFRKDRRAF1MAPK14 | |
| SCHEMBL2125179 | 0.78 | EGFR (0.61) | KITEGFRERBB2KDRMET | |
| SCHEMBL29055018 | 0.78 | ENPP1 (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGKIT | |
| SCHEMBL30080208 | 0.78 | ENPP1 (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGKIT | |
| SCHEMBL5569012 | 0.78 | EGFR (0.72) | EGFRERBB2AURKAAURKBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | PIK3CD 978/4885PIK3CA 1206/4885PIK3CB 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.